secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0001193125-22-185058
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 screens first patient in pivotal Phase 2/3 trial of epetraborole for refractory MAC lung disease
--------------------------------------------------------------------------------

- Epetraborole is a once-daily oral therapy with novel MOA for treatment-refractory MAC lung disease, the most common NTM lung disease.
- Phase 2/3 adaptive trial (EBO-301) targets ~314 patients; Phase 2 topline expected mid-2023, Phase 3 mid-2024.
- Epetraborole has FDA QIDP, Fast Track, and Orphan Drug designations; plans to use LPAD pathway for streamlined approval.
- First patient screened; Phase 2 will assess clinical response, safety, and PK to inform Phase 3 design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312522185058/0001193125-22-185058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312522185058/d322412d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-185058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer